Investigator

Monica Miozzo

Director medical Genetics · Università degli Studi di Milano, Health Sciencesa

MMMonica Miozzo
Papers(1)
Copy number alteratio…
Collaborators(10)
Robert FruscioChiara PesentiDeborah LenociDionyssios KatsarosFabio LandoniFederico AgostinisFulvio BorellaJames D. BrentonLara Veronica Venturi…Luca Beltrame
Institutions(7)
University Of MilanMario Negri Institute…University Of TurinUniversity Of Milano …University Of PaduaUniversity of Cambrid…IRCCS Humanitas Resea…

Papers

Copy number alterations in stage I epithelial ovarian cancer highlight three genomic patterns associated with prognosis

Stage I epithelial ovarian cancer (EOC) encompasses five histologically different subtypes of tumors confined to the ovaries with a generally favorable prognosis. Despite the intrinsic heterogeneity, all stage I EOCs are treated with complete resection and adjuvant therapy in most of the cases. Owing to the lack of robust prognostic markers, this often leads to overtreatment. Therefore, a better molecular characterization of stage I EOCs could improve the assessment of the risk of relapse and the refinement of optimal treatment options. 205 stage I EOCs tumor biopsies with a median follow-up of eight years were gathered from two independent Italian tumor tissue collections, and the genome distribution of somatic copy number alterations (SCNAs) was investigated by shallow whole genome sequencing (sWGS) approach. Despite the variability in SCNAs distribution both across and within the histotypes, we were able to define three common genomic instability patterns, namely stable, unstable, and highly unstable. These patterns were based on the percentage of the genome affected by SCNAs and on their length. The genomic instability pattern was strongly predictive of patients' prognosis also with multivariate models including currently used clinico-pathological variables. The results obtained in this study support the idea that novel molecular markers, in this case genomic instability patterns, can anticipate the behavior of stage I EOC regardless of tumor subtype and provide valuable prognostic information. Thus, it might be propitious to extend the study of these genomic instability patterns to improve rational management of this disease.

167Works
1Papers
11Collaborators

Positions

2021–

Director medical Genetics

Università degli Studi di Milano · Health Sciencesa

2021–

Full Professor in Medical Genetics

Università degli Studi di Milano Dipartimento di Matematica Federigo Enriques · DEPARTMENT OF HEALTH SCIENCES

2018–

Full Professor in Medical Genetics

Università degli Studi di Milano

1999–

Researcher in Medical Genetics

Università degli Studi di Milano

1987–

Research Fellow

Fondazione IRCCS Istituto Nazionale dei Tumori · Experimental Oncology

Education

1998

PhD Molecular and Cellular Biology

Università degli Studi di Milano

1994

Specialist Degree in Medical Genetics

Università degli Studi di Milano

1987

MA degree in Biological Science

Università degli Studi di Milano

Links & IDs
0000-0002-6523-4575

Scopus: 7006895458